Publications

November 2012
Supplement

Amylin Pharmaceuticals (B)

By: Richard G. Hamermesh and Carin-Isabel Knoop

Amylin Pharmaceuticals brought two first-in-class diabetes drugs to market, Byetta and Symlin, in 2005, which were sold in over 80 countries with $650.7 million in sales by 2011. However, the company remained unprofitable as sales plateaued. The small pharmaceutical... View Details

Keywords: Pharmaceuticals; Bristol-Myers Squibb; Health Care and Treatment; Pharmaceutical Industry; United States

September 2012 (Revised November 2014)
Case

Cialis Lifecycle Management: Lilly's BPH Dilemma

By: Elie Ofek and Natalie Kindred

How should Eli Lilly further develop and market a new indication of its highly successful erectile-dysfunction (ED) drug, Cialis, without confusing Cialis's hard-won brand equity with physicians and patients? With the final stages of clinical trials for the new... View Details

Keywords: Product Positioning; Attitudes; Brands and Branding; Pharmaceutical Industry; United States

September 2012
Case

SCMS: Battling HIV/AIDS in Africa

By: Ananth Raman, Noel Watson, Santiago Kraiselburd and Emmanuel Akili

In 2005, USAID and the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), created the Supply Chain Management System (SCMS) to procure and distribute essential medicines and supplies; provide technical assistance to transform existing supply chains; and... View Details

September 2012 (Revised August 2015)
Case

Shanghai Pharmaceuticals

By: Regina E. Herzlinger and Natalie Kindred

Shanghai Pharmaceuticals (SPH), a vertically integrated Chinese pharmaceutical conglomerate, was considering its strategic options in the context of a rapidly evolving industry, policy, and economic environment. The company—essentially a collection of subsidiaries... View Details

Keywords: Business Subsidiaries; Business Conglomerates; Vertical Integration; Decision Choices and Conditions; Mergers and Acquisitions; Consolidation; Health Care and Treatment; Global Strategy; State Ownership; Pharmaceutical Industry; Pharmaceutical Industry; Shanghai; United States; Europe

August 2012 (Revised August 2024)
Case

ABC Pharmaceuticals

By: Regina E. Herzlinger and Erik R. Sparks

This case asks students to price a new drug that is in Stage II of its clinical trials. It contains detailed estimates of the time required and costs for all the steps needed to commercialize a drug in the U.S. Students will learn virtually all the steps required to... View Details

Keywords: Drug Development; Price; Product; Product Launch; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry

August 2012 (Revised January 2013)
Module Note

Note on Pharmaceutical Reimbursement in the U.S.

By: Regina Herzlinger and Drew Cronin-Fine

May 2012 (Revised August 2014)
Case

McKesson

By: Regina E. Herzlinger and Natalie Kindred

McKesson, a large, diversified drug distribution and health care IT company, is considering development of new business offerings to help private practice physicians remain independent. The company, with $122 billion in 2010 revenues, just made its first foray into... View Details

Keywords: Health Care Industry; Health Care Policy; Organizational Transformations; Health Services; Health Care and Treatment; Business Model; Service Operations; Change Management; Corporate Strategy; Information Technology; Policy; Pharmaceutical Industry; Pharmaceutical Industry; United States

April 2012 (Revised May 2012)
Case

Merck: Operating Science-Based Business

By: Ananth Raman, Inga Maurer and William Schmidt

Merck is known for its commitment to investing in basic R&D. Are Merck's long-term investments justifiable when the firm faces extreme earnings pressure? View Details

Keywords: Science-Based Business; Management; Research and Development; Business and Shareholder Relations; Operations; Pharmaceutical Industry; United States

8 Mar 2012
Other Presentation

Competing by Saving Lives: How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health

By: Michael E. Porter

How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health View Details

Keywords: Society; United States

March 2012
Article

Managing Political Risk in Global Business: Beiersdorf 1914-1990

By: Geoffrey Jones and Christina Lubinski

This article is concerned with business strategies of political risk management during the twentieth century. It focuses especially on Beiersdorf, a pharmaceutical and skin care company in Germany. During World War I, the expropriation of its brands and trademarks... View Details

Keywords: Business Strategy; Government and Politics; Risk Management; Brands and Branding; Problems and Challenges; Communication Technology; Cost; Trademarks; Strategy; Pharmaceutical Industry; Germany

Find at Harvard

2012
Chapter

Evidence from the Firm: A New Approach to Understanding Corruption

By: Shawn A. Cole and Anh Tran

Due to its clandestine nature, most of what we understand about corruption comes from survey evidence and self-reported perceptions of corruption: this limits both the range of questions that can be asked and the precision of answers that can be provided. This chapter... View Details

Keywords: Measurement and Metrics; Crime and Corruption; Organizations; Ownership; Asia

2011
Article

Strategic Change and the Jazz Mindset: Exploring Practices That Enhance Dynamic Capabilities for Organizational Improvisation

By: Ethan S. Bernstein and Frank J. Barrett

How can leaders adopt a mindset that maximizes learning, remains responsive to short-term emergent opportunities, and simultaneously strengthens longer-term dynamic capabilities of the organization? This chapter explores the organizational decisions and practices... View Details

2011
Working Paper

Managing Political Risk in Global Business: Beiersdorf 1914-1990

By: Geoffrey Jones and Christina Lubinski

This working paper examines corporate strategies of political risk management during the twentieth century. It focuses especially on Beiersdorf, a German-based pharmaceutical and skin care company. During World War I the expropriation of its brands and trademarks... View Details

Keywords: History; Risk Management; Business History; Multinational Firms and Management; Corporate Strategy; Intellectual Property; Cooperation; Business and Government Relations; Germany

May 2011
Case

The Morrison Company

By: Steven C. Wheelwright and Paul Meyers

The Morrison Company develops and manufactures radio frequency identification tags (RFID) known as smart labels for the retail and pharmaceutical industries. RFID technology is a fast-growing and increasingly competitive industry. Sales have risen dramatically over the... View Details

Keywords: Quantitative Analysis; Technology; Operations Management; Product Lines; Manufacturing; Capacity Planning; Production Planning; Information Technology; Strategy; Production; Organizational Structure; Infrastructure; Product Development; Information Infrastructure; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry

May 2011 (Revised July 2012)
Exercise

Remicade/Simponi: Confidential Instructions for Merck

By: Guhan Subramanian and Rhea Ghosh

This two-party negotiation exercise features a real-life dispute between Merck and Johnson & Johnson regarding European distribution rights to two highly lucrative drugs. View Details

Keywords: Price; Rights; Agreements and Arrangements; Negotiation Deal; Problems and Challenges; Risk and Uncertainty; Pharmaceutical Industry

April 2011 (Revised April 2015)
Case

Cipla 2011

By: Rohit Deshpande, Sandra J. Sucher and Laura Winig

Dr. Yusuf Hamied, head of the Indian pharma and generics manufacturing company Cipla, is weighing options for how to continue to support the global fight against HIV/AIDS while positioning his company for growth in a changing regulatory landscape. View Details

Keywords: Leadership; Leading Change; Leadership Style; Management Teams; Governance Compliance; Corporate Strategy; Pharmaceutical Industry

April 2011
Teaching Note

Office of Technology Transfer - Shanghai Institutes for Biological Sciences (TN)

By: Willy Shih and Sen Chai

Teaching Note for 611057. View Details

Keywords: Patents; Rights; Infrastructure; Multinational Firms and Management; Research and Development; Complexity; Commercialization; Technology Adoption; Motivation and Incentives; Pharmaceutical Industry; Pharmaceutical Industry; Shanghai

March 2011 (Revised June 2012)
Case

Office of Technology Transfer - Shanghai Institutes for Biological Sciences

By: Willy Shih, Sen Chai, Kamen Bliznashki and Courtney Hyland

Gordon Zong is trying to teach Chinese universities and research institutes how to do effective technology transfer and IP licensing, but he is trying to do it in an environment with weak property rights and an underdeveloped support infrastructure. As the managing... View Details

Keywords: Multinational Firms and Management; Patents; Knowledge Management; Law Enforcement; Business and Government Relations; Research and Development; Pharmaceutical Industry; Pharmaceutical Industry; China

March 2011 (Revised February 2012)
Case

Innovation and Growth at Actelion Ltd.

By: Gary P. Pisano, Daniela Beyersdorfer and Ruth Dittrich

In late 2010, Jean-Paul Clozel, CEO of the Swiss biotech pharmaceuticals firm Actelion, looks back on a successful decade. The small venture that he had started with a few of his scientist colleagues in the late 1990s to discover novel medicine in a research-driven... View Details

Keywords: Business Model; Talent and Talent Management; Innovation and Management; Leadership; Growth and Development Strategy; Product Development; Organizational Culture; Research and Development; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland